Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novocure Ltd Ord Sh (NVCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,947,202
  • Shares Outstanding, K 93,014
  • Annual Sales, $ 177,030 K
  • Annual Income, $ -61,660 K
  • 36-Month Beta 3.25
  • Price/Sales 20.84
  • Price/Cash Flow N/A
  • Price/Book 42.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.16
  • Number of Estimates 3
  • High Estimate -0.15
  • Low Estimate -0.17
  • Prior Year -0.12
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.41 +16.82%
on 01/22/19
54.00 -1.76%
on 02/19/19
+6.60 (+14.21%)
since 01/18/19
3-Month
26.02 +103.88%
on 11/20/18
54.00 -1.76%
on 02/19/19
+24.30 (+84.52%)
since 11/19/18
52-Week
19.20 +176.30%
on 02/23/18
54.00 -1.76%
on 02/19/19
+31.55 (+146.74%)
since 02/16/18

Most Recent Stories

More News
Novocure Announces Fourth Quarter and Full Year 2018 Operating Statistics, Preliminary Net Revenues and Provides Company Update

--Fourth quarter and full year 2018 financial results to be reported Thursday, Feb. 28, 2019

NVCR : 53.05 (-0.26%)
JPM : 105.18 (-0.35%)
Novocure to Participate in the 37th Annual J.P. Morgan Healthcare Conference

Novocure (NASDAQ: NVCR) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco. William Doyle, Novocure's Executive Chairman, will...

NVCR : 53.05 (-0.26%)
JPM : 105.18 (-0.35%)
Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields

Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce four inaugural Tumor Treating Fields research grants. The grants represent a joint effort to promote...

NVCR : 53.05 (-0.26%)
PIMCO Closed-End Funds Declare Special Year-End Distribution

The Board of Trustees/Directors of the PIMCO closed-end funds (each, a "Fund" and, collectively, the "Funds") has declared a special year-end distribution for certain Fund's common shares as summarized...

IPG : 23.29 (-0.38%)
NGVC : 14.86 (-1.39%)
STC : 42.79 (+0.16%)
ATUS : 21.46 (-0.60%)
RBA : 36.48 (-0.44%)
MHK : 139.71 (+0.36%)
NVCR : 53.05 (-0.26%)
CVSI : 4.7200 (-3.87%)
AC : 41.68 (-1.07%)
BSX : 39.86 (-0.37%)
HON : 153.28 (-0.03%)
POTND : 0.0200 (+32.45%)
PRTT : 1.0000 (-20.00%)
TARSD : 0.2033 (-1.64%)
NKE : 84.57 (-0.95%)
ROIC : 17.80 (-0.11%)
DGX : 88.05 (+0.27%)
EIX : 61.65 (+1.90%)
GARLF : 0.0820 (-2.61%)
MRNA : 20.83 (-2.85%)
MSPC : 0.0001 (-50.00%)
RYAAY : 73.66 (+1.85%)
BA : 416.26 (-0.41%)
BDC : 56.58 (-0.11%)
BC : 51.90 (+0.91%)
OXFD : 16.75 (-0.83%)
NDAQ : 87.82 (+0.07%)
TTOO : 3.74 (+1.36%)
DMAC : 3.45 (+9.18%)
CMCM : 7.30 (+3.11%)
ALGN : 255.24 (+0.11%)
ABM : 36.35 (+0.41%)
RTN : 184.62 (+0.01%)
IESC : 18.78 (+0.91%)
KIDS : 37.57 (+1.43%)
CYL.VN : 0.155 (unch)
FLIR : 52.04 (-0.71%)
NETC.CN : 0.105 (+5.00%)
SLCA : 15.25 (+5.61%)
BANX : 20.90 (-1.65%)
APOG : 36.38 (+0.30%)
RBBN : 6.15 (+5.67%)
SPLIF : 0.2173 (-2.03%)
SO : 48.92 (+0.74%)
SNWV : 0.1885 (-0.79%)
ACB : 6.93 (-1.70%)
CE : 100.95 (+0.69%)
QILFF : 0.1850 (+1.04%)
QILFD : 0.2331 (-29.98%)
MANH : 54.49 (+0.48%)
MKL : 1,016.87 (+0.70%)
HAL : 31.70 (-0.47%)
LZB : 32.22 (+2.58%)
INTC : 51.40 (-0.50%)
APHQF : 11.5700 (-3.05%)
AMZN : 1,627.58 (+1.22%)
ACHC : 28.09 (-1.13%)
TX : 31.43 (+0.10%)
SRPT : 140.26 (+1.31%)
JOUT : 66.00 (-0.06%)
CCAN : 0.2448 (+2.00%)
OBMP : 0.0091 (-3.19%)
ELY : 16.74 (+1.58%)
DY : 62.88 (-0.38%)
HIPH : 0.0530 (-1.85%)
POTN : 0.1750 (+10.06%)
JWN : 45.25 (+1.82%)
SYF : 31.76 (+0.03%)
AQUA : 13.07 (+1.32%)
NWVCF : 1.2878 (+2.21%)
USYNF : 3.1500 (+5.77%)
EMR : 67.89 (-0.61%)
BXE : 0.46 (-3.16%)
HSY : 109.69 (+0.31%)
EW : 177.03 (-0.42%)
SCQBD : 0.7420 (+1.08%)
PTS.TO : 14.47 (-0.41%)
PSX : 96.75 (+0.79%)
MVIS : 1.12 (+2.75%)
PCI : 22.91 (+0.53%)
PCN : 16.35 (+0.31%)
AVT : 44.16 (+0.09%)
MGNX : 22.15 (+1.42%)
ICBK : 18.85 (+2.00%)
DLR : 116.41 (+1.20%)
RHI : 67.45 (+0.70%)
YVR : 2.01 (-4.74%)
PTY : 16.73 (unch)
PDI : 31.24 (-0.03%)
TNXP : 1.94 (unch)
GBT : 50.71 (-2.69%)
QI.VN : 0.290 (-27.50%)
TSRO : 74.96 (+0.03%)
RHP : 84.97 (+0.27%)
NKTR : 42.81 (+2.69%)
GOOG : 1,118.56 (+0.44%)
JBLU : 17.93 (-0.17%)
IGC : 2.49 (unch)
WBT : 15.85 (+4.07%)
WRY.VN : 0.100 (+66.67%)
SAPIF : 31.1174 (+0.61%)
WSO : 144.55 (+0.83%)
LMT : 305.18 (-0.67%)
CMCSA : 37.55 (-0.58%)
HSDT : 7.57 (-1.30%)
GWRE : 92.71 (-0.22%)
CLGX : 39.76 (+0.05%)
FNSR : 23.66 (+1.20%)
SONS : 7.83 (+2.76%)
DEWM : 0.0010 (-16.67%)
SLG : 92.09 (+0.53%)
UPS : 110.77 (-0.09%)
PFN : 10.27 (+0.39%)
KMB : 119.57 (+0.95%)
ANZ.VN : 0.075 (+7.14%)
TAOP : 1.08 (-0.92%)
NSU : 4.52 (+0.22%)
CBDS : 3.3300 (-3.62%)
CTXS : 106.28 (-0.20%)
PCOM : 10.87 (-0.09%)
HTHT : 33.48 (+1.64%)
MAN : 84.59 (+0.19%)
CNK : 36.77 (-1.45%)
AMAT : 39.30 (+0.51%)
FMCC : 2.6100 (+1.56%)
MRK : 79.24 (-0.71%)
ATOS : 1.48 (-1.99%)
WTCRF : 0.0138 (unch)
MLRKF : 0.0736 (+19.09%)
GAZ-UN.VN : 0.600 (unch)
MEOH : 57.03 (-0.35%)
COOL : 17.33 (-0.69%)
SAVE : 62.34 (+1.09%)
PCRX : 39.94 (-1.82%)
RNLSY : 13.3400 (-0.89%)
COL : 141.04 (-0.42%)
COR : 104.80 (+2.02%)
IDXG : 0.95 (+2.15%)
MCD : 179.25 (-0.40%)
ETST : 0.7000 (-2.78%)
QNIIF : 0.7100 (-2.62%)
PII : 86.79 (+0.01%)
AMRS : 4.53 (-8.67%)
SON : 59.96 (+1.78%)
MCK : 136.30 (+0.55%)
APHA : 9.71 (+1.15%)
MCO : 167.96 (-0.77%)
GSKY : 10.45 (+0.19%)
LH : 149.79 (-0.25%)
SAP.TO : 42.02 (+0.94%)
ODFL : 149.53 (+2.16%)
NEU : 430.47 (-0.10%)
ORTX : 16.47 (+8.00%)
BXE.TO : 0.64 (-3.03%)
GWPRF : 12.8000 (+0.08%)
PZN : 8.99 (+0.45%)
RBX.VN : 0.080 (+6.67%)
RNG : 104.00 (-0.64%)
SPG : 182.23 (-0.62%)
TRVN : 1.49 (-3.25%)
AMC : 13.20 (-4.28%)
UTX : 128.64 (+0.69%)
AMD : 23.95 (+1.14%)
NDLS : 7.32 (-2.53%)
MPWR : 136.42 (-1.49%)
KGKG : 0.0750 (-5.06%)
FRO-UN.VN : 0.550 (+1.85%)
DMCAF : 0.3840 (+0.52%)
IRMTF : 11.9721 (-0.40%)
BOX : 24.42 (-0.73%)
IQST : 1.2500 (-15.54%)
ASPS : 25.41 (+0.87%)
HMNY : 0.0071 (-1.39%)
ROP : 311.23 (-0.23%)
GOVB : 14.0500 (-10.79%)
PKO : 26.18 (+0.11%)
MYGN : 31.48 (+0.06%)
CRL : 141.13 (+0.19%)
GLPH : 0.0175 (+15.89%)
BXXRF : 0.0102 (+100.00%)
ADTN : 14.56 (-0.88%)
GRNH : 0.0190 (-4.04%)
NS : 26.85 (+1.40%)
LTS : 3.04 (+3.05%)
INT : 26.18 (+1.71%)
INPX : 1.53 (+2.00%)
GSPT : 0.0400 (unch)
MRO.VN : 0.095 (+11.76%)
COST : 218.12 (+0.76%)
EFX : 109.32 (+0.01%)
BMRN : 91.85 (-2.28%)
SPGI : 197.65 (-0.34%)
IGCC : 0.3710 (-1.07%)
PYPL : 95.02 (+0.12%)
LHSIF : 0.8320 (+0.24%)
TDY : 235.45 (-0.39%)
AZPN : 99.68 (-0.36%)
ENW.VN : 1.700 (+2.41%)
DMA.VN : 4.630 (-2.11%)
SNAP : 9.28 (+1.75%)
KSU : 109.55 (+1.87%)
MERC : 14.77 (-1.40%)
DVA : 59.14 (+0.07%)
UNI.VN : 3.700 (-0.27%)
MGI : 2.44 (+0.41%)
IGAP : 0.4900 (-19.67%)
FIT : 6.38 (-0.47%)
RAD : 0.78 (-2.25%)
LDSR : 0.0024 (unch)
CYLYF : 0.1149 (+8.29%)
PMX : 11.86 (+1.80%)
ROBXF : 0.1851 (+262.94%)
BRO : 29.12 (+0.21%)
Sub-Group Analysis of Novocure's EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune(R) Predicted Increased Survival

--Monthly usage was a predictor of survival, independent of other prognostic factors such as Karnofsky Performance Score, age, or MGMT methylation status

NVCR : 53.05 (-0.26%)
Zai Lab and Novocure Awarded Deal of the Year

Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, and Novocure Limited (NASDAQ: NVCR) today announced that they have received the Deal of the Year Award at the 9 Annual...

NVCR : 53.05 (-0.26%)
ZLAB : 28.63 (+2.07%)
Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China

Novocure (NASDAQ:NVCR) announced today that Novocure and Zai Lab have received the Deal of the Year Award from BayHelix at a ceremony during the 5th annual BioCentury China Healthcare Summit...

NVCR : 53.05 (-0.26%)
ZLAB : 28.63 (+2.07%)
Novocure and Zai Lab to Host Investor Event

Novocure (NASDAQ: NVCR) announced today that it will host an investor event with Zai Lab on Nov. 14, 2018, in Shanghai, China. William Doyle, Novocure's Executive Chairman, Dr. Samantha Du,...

NVCR : 53.05 (-0.26%)
ZLAB : 28.63 (+2.07%)
New Research Coverage Highlights HomeStreet, Cousins Properties, Carbo Ceramics, Cowen Group, CTS, and NovoCure -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of HomeStreet, Inc. (NASDAQ:HMST),...

CRR : 4.44 (+0.68%)
CTS : 30.33 (-3.53%)
NVCR : 53.05 (-0.26%)
HMST : 27.91 (+1.49%)
CUZ : 9.53 (+0.53%)
COWN : 16.98 (+3.28%)
NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of 13.33% and -1.30%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

NVCR : 53.05 (-0.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade NVCR with:

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

2nd Resistance Point 54.61
1st Resistance Point 53.83
Last Price 53.05
1st Support Level 52.44
2nd Support Level 51.84

See More

52-Week High 54.00
Last Price 53.05
Fibonacci 61.8% 40.71
Fibonacci 50% 36.60
Fibonacci 38.2% 32.49
52-Week Low 19.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar